Smeshnie Scenki Pro Povarov Konditerov
Glass-fused to steel tanks can be used as a stable fire tank for sprinkler systems. They are designed as aboveground cylindrical tanks. Modular construction allows the construction of 6 m3 tanks up to a 4500 m3 tank. The tank forms a concrete floor made of either waterproof concrete or with an impermeable foil. The shell of the tank is made of bolted glass-fused to steel sheets sealed by silicone sealant.
Write something about yourself. No need to be fancy, just an overview. No Archives Categories.
The roof is light from corrugated sheet metal. Accessories includes an exit ladder on the roof, inspection inputs, vent head, flange neck and overflow piping. The components of the delivery can be, according to the customer’s request, combination of thermal insulation with electric heating. The advantages of these tanks includes: – quick assembly – installation in difficult-to-reach areas (eg cellars) – durability of surface protection – Quick liquidation in case of system cancellation – multiple use Our tanks will satisfy all requirements for water storage for stable fire extinguishing systems. Tank construction is performed according to EN standards, or according to FM Global Standard.
Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A.
Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R.
Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.
Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m 2 once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks (ddAC) for four cycles, and were randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for four cycles and/or bevacizumab 10 mg/kg once every 2 weeks for nine cycles. Effects of adding these agents on pCR breast (ypT0/is), pCR breast/axilla (ypT0/isN0), treatment delivery, and toxicities were analyzed. Patients assigned to either carboplatin or bevacizumab were less likely to complete wP and ddAC without skipped doses, dose modification, or early discontinuation resulting from toxicity.
Grade ≥ 3 neutropenia and thrombocytopenia were more common with carboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative complications with bevacizumab. Employing one-sided P values, addition of either carboplatin (60% v 44%; P =.0018) or bevacizumab (59% v 48%; P =.0089) significantly increased pCR breast, whereas only carboplatin (54% v 41%; P =.0029) significantly raised pCR breast/axilla. More-than-additive interactions between the two agents could not be demonstrated. Breast cancer (TNBC), characterized by absent or minimal expression of estrogen (ER) and progesterone receptors (PgRs) and human epidermal growth factor receptor 2 (HER2), accounts for 15% to 20% of invasive breast cancers diagnosed in the United States. It is more common in younger women, African Americans, Hispanics, and BRCA1-mutation carriers. With no targetable characteristic molecular abnormalities yet identified, standard treatment for TNBC remains chemotherapy. Deepolis torgovaya karta.